Member Info for Uncanny

My last two posts have been removed?

That should be efficacy and efficiency I guess!

Yes Bads, its all about the body language from Align. If they are uber positive then game on!

Align will almost certainly have signed a NDA so may be compromised on what they can say.

Possibly why they cancelled the funding facility or is that because of VAL401 JV is next month? I have a good feeling we will have a bucket load of more positive announcements shortly that will lift the share price through resistance and then keep the momentum going! 201 Update CTII 401 JV More patent protection 101 and 301 update 201 JV Government Funding Takeover? Exciting times!

Maybe the allocation hasn’t been confirmed yet, but i’d be gobsmacked if VAL didn’t receive something!

Monkey grinder sounds a bit gruesome!

Roses,mmmmm ..... no my old fruit. If they were Goldmans or Deutsche then yes.

FFS, Align will not get any inside info, nor can they release it nor will VAL be stupid enough to face a court sentence in giving anything non-public info away! They are an tuppence happenny research firm with no clout or influence whatsoever.

I’ll be very surprised at news on Friday, bwtfdik! July is the month IMHO, which is only 9 working says away from the start. 201 update and 401 JV.

Need to break 4p!

So the company has told both Time and Russell on minent news? What news please?

The rest: “Amgen is also trying to push Kyprolis into a second-line indication for multiple myeloma. The drug currently is approved for third-line or above, and mixed data between its ASPIRE and FOCUS studies doesn't indicate which way U.S. and EU regulators will rule, either. Either way, expect Amgen to remain a key oncology player for the time being. No. 1: Roche (NASDAQOTH:RHHBY): $25.4 billion in total oncology drug sales Sitting atop the list of annual cancer drug sales is Swiss-based Roche, which generated more than one quarter of all oncology drug sales in 2013 by itself! But, should we really be surprised with Roche currently possessing a clinical pipeline that's more than 100 trials deep, of which around 60 of those studies are for cancer indications? I'm not shocked one bit! SOURCE: ROCHE. In 2013, four of Roche's top-five selling pharmaceutical products were geared at fighting cancer and improving lives. These include MabThera/Rituxan for non-Hodgkin's lymphoma ($8.1 billion), Avastin, which can be used for colorectal, breast, kidney, lung, and a host of other cancer types ($7.3 billion), Herceptin, a commonly-used therapy to treat HER2-positive breast cancer ($7.1 billion), and Xeloda for colorectal, colon, or breast cancer ($1.8 billion). Note that my own currency-translated figures may add up to a bit more than PMLiVE report's data, which tried to remove currency fluctuations from their calculations. Roche has made it its focus to develop new and innovative cancer drugs, as well as expand the possible label indications for its existing drugs. For example, Perjeta is an extremely intriguing new cancer compound for HER2-positive breast cancer patients. When combined with Herceptin and docetaxel in the CLEOPATRA trial for advanced HER2-positive breast cancer patients, it led to a median overall survival of 56.5 months. This was nearly a 16-month improvement relative to the group that didn't receive Perjeta, and it's the longest reported period of median overall survival in any advanced cancer study -- ever! Long story short, Roche is an absolute powerhouse when it comes to cancer drug innovation, and that could be good news for investors, and great news for those unfortunate enough to be afflicted by cancer.”

Very excited to see who will pay top dollar for 401, but my guess is one of the three below:. “To this end, the good news is that pharmaceutical companies are listening loud and clear. Oncology drug development is a cornerstone to the success of quite a few pharmaceutical companies, not only because it'll keep them profitable, but because it'll save lives and fund additional research into curing new types of cancers and other diseases. Three companies responsible for half of all global cancer drug sales Here's a breakdown of the three companies that controlled roughly half of all cancer drug sales in 2013. No. 3: Novartis (NYSE:NVS): $8.6 billion in total oncology drug sales Novartis' appearance on this list probably shouldn't be a huge surprise as it's been a cancer drug powerhouse for quite some time. In 2013, it counted on chronic myeloid leukemia drug Gleevec (known as Glivec overseas) for nearly $4.7 billion in global sales, but also relied on Sandostatin (for acromegaly) and Afinitor (breast cancer) for $1.6 billion and $1.3 billion in global sales. What sets Novartis apart is its deep pipeline of phase 2 and 3 cancer drugs as well as its announced deal with GlaxoSmithKline to boost its cancer drug portfolio and pipeline. Novartis will be sending its vaccines business to GlaxoSmithKline and setting up a joint-venture for its consumer health products segment in exchange for Glaxo's oncology program. The deal nets Glaxo some much-needed cash (just shy of $8 billion when the swap is complete), but more importantly, it establishes Novartis as a dominant cancer drug player. Glaxo's melanoma drugs mekinist and tafinlar will be a perfect complement to its growing portfolio of products designed to improve patients' quality of life. Novartis' pipeline also currently has more than a dozen experimental oncology drugs in mid- or late-stage studies, meaning multiple new catalysts and life-improving cancer drugs could be right around the corner.” No. 2: Amgen (NASDAQ:AMGN): $11.9 billion in total oncology drug sales Surprised by Amgen's ranking? Don't be, as the company has a long history of supportive cancer care therapies. Neulasta (known as Neupogen overseas), is a roughly $6 billion per year drug designed to stimulate white blood cell growth for patients currently undergoing chemotherapy. Aranesp is responsible for another $2 billion in annual sales and helps treat anemia in patients undergoing chemotherapy and in kidney failure. And of course, we can't forget multiple myeloma drug Kyprolis, which was acquired when Amgen purchased Onyx Pharmaceuticals for a cool $10.4 billion. SOURCE: AMGEN. Looking ahead, Amgen has a healthy lineup of new cancer drug hopefuls. Its immunotherapy product talimogene laherparepvec, or T-Vec, would appear to me to have a better than 50-50 shot at approval in the U.S. and abroad as a treatment for metastatic melanoma. T-Vec could also demonstrate plenty of other applications as a

Not true Tricky. The market take £50 to £100 out of the value to sell and then buy back in your ISA so you don’t have to risk the spread. Just commission and stamp duty to pay as well.

July Tricky!

Yes, strangely TA does work because it is a self-fulfilling prophecy which creates its own momentum. VAL needs news and break 4p and we are in to blue sky. Higher first target is 8p then 18p and then wooooosh!

“Watch out for news to land before Friday!“

Yes noise, it was a multitude of things in 201 - efficacy, no side effects, easy administration, safe and relatively pain free. Ticks

I think we will easily have a 5 bagger or more in the next 6 months, with July being pinnacle and approacing in just 10 days! The price action today is simply a little noise with the biggest trade of 435,000 being a buy. Low volume and roll on JV and 201.